About
Medasense offers a technology that enables clinicians to optimize and personalize pain control and avoid overmedication. Medasense's flagship product, the PMD-200 with its NOL index, is a platform that objectively monitors and quantifies the patient's pain response by means of artificial intelligence and a proprietary noninvasive sensor platform. The PMD-200 is used to optimize pain management in operating rooms and critical care settings, where patients are unable to communicate. The PMD-200 is distributed in Europe exclusively by Medtronic. It is also cleared for marketing in Canada, Latin America, Israel, and Australia. It enables connectivity with Philips patient monitors. Clinical studies have demonstrated its impact on patient safety and outcomes, including opioid sparing.
Funding history · 5 rounds · $33.5M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is Medasense Biometrics' core product?
- Medasense Biometrics' flagship product is the PMD-200, which uses its NOL index. This platform objectively monitors and quantifies a patient's pain response through artificial intelligence and a noninvasive sensor platform.
- In which regions is Medasense Biometrics' PMD-200 cleared for marketing?
- The PMD-200 is cleared for marketing in Canada, Latin America, Israel, and Australia. It is also distributed exclusively in Europe by Medtronic.
- Which company distributes Medasense Biometrics' PMD-200 in Europe?
- Medtronic exclusively distributes Medasense Biometrics' PMD-200 in Europe.
- What is the total amount of funding Medasense Biometrics has raised to date?
- Medasense Biometrics has raised a total of $33.5 million USD across multiple funding rounds. For a full financing history, users can refer to startupim.
- When did Medasense Biometrics secure marketing approval for its NOL Pain Response Monitoring in Brazil?
- Medasense Biometrics secured marketing approval for its NOL Pain Response Monitoring in Brazil in October 2020.
- Which company's patient monitors are compatible with Medasense Biometrics' technology?
- Medasense Biometrics announced compatibility with Philips IntelliVue patient monitors in January 2019.
- When did the FDA authorize the marketing of Medasense Biometrics' NOL technology?
- The FDA authorized the marketing of Medasense Biometrics' NOL technology to measure pain in anesthetized patients in February 2023.
- How many employees does Medasense Biometrics currently have?
- Medasense Biometrics currently has 27 employees.
- When was Medasense Biometrics founded?
- Medasense Biometrics was founded in June 2008.